TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07223840: A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 222 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,739,600

Rescue Site Savings

+$4,448,800

Unlock Full NCT07223840 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07223840 Rescue Dossier →